Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 10, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader 12-month repurchase plan authorized on February 4, 2026.
Key Financial Metrics and Capital Allocation
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Specific Programme (May 6, 2026): Authorized up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Cumulative Repurchases (Feb 4 - Aug 7, 2026): 27,884,179 B shares repurchased at an average price of DKK 279.01, totaling DKK 7,780,067,909.
- Recent Activity (Aug 4 - Aug 7, 2026): 820,000 B shares repurchased for a total value of DKK 246,811,452.
- Treasury Shares: As of August 7, 2026, the company holds 41,924,876 B shares as treasury stock, representing 0.9% of total share capital.
Material Changes and Transactions
Since the last announcement on August 4, 2026, the company executed four transactions between August 5 and August 7, 2026. The average purchase price for these recent transactions ranged from DKK 294.26 to DKK 308.29. Additionally, the filing notes a net transfer of 3,144,604 shares related to employee incentive programmes during the same period; these were not part of the Safe Harbour repurchase programme.
Outlook and Management Commentary
Management reaffirms the expectation to repurchase B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026. The filing does not provide specific guidance on future revenue, earnings, or operational outlook, nor does it detail new risks or contingencies beyond the standard execution of the capital return programme.
Key Facts for Investor Verification
- Verify the remaining capacity under the DKK 15 billion programme (approximately DKK 7.22 billion remaining as of August 7, 2026).
- Confirm the impact of the 0.9% treasury share holding on earnings per share (EPS) calculations.
- Monitor the average repurchase price (DKK 279.01) against current market prices to assess capital efficiency.
- Note that the filing does not contain updated revenue, profit, or cash flow data; refer to the most recent Form 20-F or quarterly report for operational metrics.